Marex Group Limited Ordinary Shares vs Neurocrine Biosciences Inc — how do they compare? Marex Group Limited Ordinary Shares trades at $71.71 (market cap $5.12B), while Neurocrine Biosciences Inc trades at $142.39 (market cap $14.36B). The key difference: Neurocrine Biosciences Inc is far larger — about 2.8× Marex Group Limited Ordinary Shares's market cap, and Marex Group Limited Ordinary Shares pays a 0.9% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Marex Group Limited Ordinary Shares for 1 Days and Neurocrine Biosciences Inc for 23 Days on average.
| MRX | NBIX | |
|---|---|---|
Market Cap | $5.12B | $14.36B |
Volume | 647,370 | 1,237,180 |
Sector | Financials | Health |
52-Week High | $78.27 | $185.50 |
52-Week Low | $29.92 | $123.10 |
Typical Hold Time | 1 Days | 23 Days |
Enterprise Value | $8.20B | $14.37B |
Dividend Yield | 0.9% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Neurocrine Biosciences (NBIX) trades at $142.84, down 0.44% today, with strong fundamental performance including three consecutive quarterly earnings beats and robust profitability metrics. The stock shows bearish technical signals with resistance at $142-145, while maintaining excellent analyst support with 86% buy ratings and a $204 consensus target. Recent developments include pipeline advancements in Prader-Willi syndrome and executive appointments.
NBIX presents a compelling growth story with 20.9% net margins and expanding rare-disease portfolio, though faces execution risks as it diversifies beyond Ingrezza. The 43% upside to consensus target suggests significant potential, but investors must monitor pricing pressures and pipeline execution amid elevated valuation multiples.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Marex Group provides financial services across commodities, financial markets, and corporate clients. Its services include clearing, agency and execution, market making, hedging, and securities services.
Read more on MRX →Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →